Somatostatin Analogue Octreotide Enhances the Antineoplastic Effects of Tamoxifen and Ovariectomy on 7,12-Dimethylbenz(a)anthracene-induced Rat Mammary Carcinomas

Cancer Research

Volumn 54, Issue 24, 1994, Pages 6334-6337

  Pollak, M ^b   Tolcsvai, L ^a   Stolz, B ^a   Bruns, C ^a  

^a Preclinical Research   (Switzerland)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; OCTREOTIDE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; TUMOR REGRESSION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMAL; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; OCTREOTIDE; ORGAN WEIGHT; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOSTATIN; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN; UTERUS;

EID: 0028670841     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jordan, V.C. and Murphy, C.S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev. 11: 578-611, 1990.
2. Jordan, V.C. Growth factor regulation by tamoxifen is demonstrated in patients with breast cancer. Cancer (Phila.), 72: 1-2, 1993.
3. Dickson, R.B. McManaway, M.E. and Lippman, M.E. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science (Washington DC), 232: 1540-1543, 1986.
4. Friedl, A. Jordan, V.C. and Pollak, M.N. Suppression of serum IGF-I levels in breast cancer patients during adjuvant tamoxifen therapy. Eur. J. Cancer, 29: 1368-1372, 1993.
5. Pollak, M.N. Costantino, J. Polychronakos, C. Blauer, S. Guyda, H. Redmond, C. Fisher, B. and Margolese, R. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J. Natl. Cancer Inst. 82: 1963-1967, 1990.
6. Huynh, H.T. Tetenes, E. Wallace, L. and Pollak, M.N. In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res. 53: 1727-1730, 1993.
7. Pollak, M.N. Effects of adjuvant tamoxifen therapy on growth hormone and insulinlike growth factor I (IGF-I) physiology. In: S.E. Salmon (ed.), Adjuvant Therapy of Cancer, Vol. 2, pp. 43-54. Philadelphia: J.B. Lippincott Co. 1993.
8. Knabbe, C. Lippman, M.E. Wakefield, L.M. Flanders, K.C. Kasid, A. Derynck, R. and Dickson, R.B. Evidence that transforming growth factor β is a hormonally regulated negative growth factor in human breast cancer cells. Cell, 48: 417-428, 1987.
9. Pratt, S.E. and Pollak, M.N. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res. 53: 5193-5198, 1993.
10. Reichlin, S. Somatostatin. N. Engl. J. Med. 309: 1495-1501, 1983.
11. Lamberts, S.W.J. Krenning, E.P. and Reubi, J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12: 450-482, 1991.
12. Weckbecker, G. Raulf, F. Stolz, B. and Bruns, Ch. Somatostatin analogs for diagnosis and treatment of cancer (Review). Pharmacol. Ther. 60: 245-264, 1993.
13. Schally, A.V. Oncological applications of somatostatin analogues. Cancer Res. 48: 6977-6985, 1988.
14. Setyono-Han, B. Henkelman, M.S. Foekens, J.A. and Klijn, G.M. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res. 47: 1566-1570, 1987.
15. Weckbecker, G. Liu, R. Tolcsvai, L. and Bruns, C. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res. 52: 4973-4978, 1992.
16. Weckbecker, G. Tolcsvai, L. Liu, R. and Bruns, Ch. Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995). Metabolism, 41: 99-103, 1992.
17. Szepeshazi, K. Milovanovic, S. Lapis, K. Groot, K. and Schally, A.V. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res. Treat. 21: 181-192, 1992.
18. Van Eijck, C.H. Krenning, E.P. Bootsma, A. Lindemans, J. Jeekel, J. Reubi, J.C. and Lamberts, S.W.J. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet, 343: 640-643, 1994.
19. Jordan, V.C. and Allen, K.E. Evaluation of the antitumour activity of the non-steroidal antiestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur. J. Cancer, 16: 239-251, 1980.
20. Welsch, C.W. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res. 45: 3415-3443, 1985.
21. Bruns, C. Dietl, M.M. Palacios, J.M. and Pless, J. Identification and characterization of somatostatin receptors in neonatal rat long bones. Biochem. J. 265: 39-44, 1990.
22. Jordan, V.C. Effect of tamoxifen (ICI 46.474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur. J. Cancer, 12: 419-424, 1976.
23. Pollak, M.N. Perdue, J.F. Margolese, R.G. Baer, K. and Richard, M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett. 38: 223-230, 1987.
24. Harris, J.R. Morrow, M. and Bonadonna, G. Cancer of the Breast. In: V.T. DeVita, Jr. S. Hellman, and S.A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 4, pp. 1264-1332. Philadelphia: J.B. Lippincott Co. 1993.
25. Bakker, G.H. Setyono-Han, B. Foekens, J.A. Portengen, H. van Putten, W.L. de Jong, F.H. Lamberts, S.W. Reubi, J.C. and Klijn, J.G. The somatostatin analog Sandostatin (SMS 201-995) in treatment of DMBA-induced rat mammary tumors. Breast Cancer Res. Treat. 17: 23-32, 1990.
26. Lee, C. Lapin, V. Oyasu, R. and Battifora, H. Effect of ovariectomy on serially transplanted rat mammary tumors induced by 7, 12-dimethylbenzanthracene. Eur. J. Cancer Clin. Oncol. 17: 801-808, 1981.
27. Lee, M.T. Liebow, C. Kamer, A.R. and Schally, A.V. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc. Natl. Acad. Sci. USA, 88: 1656-1660, 1991.
28. Pollak, M.N. Polychronakos, C. and Guyda, H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-1. Anticancer Res. 9: 889-892, 1989.
29. Tannenbaum, G.S. Gurd, W. Lapointe, M. and Pollak, M.N. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology, 130: 3395-3401, 1992.
30. Huynh, H.T. and Pollak, M.N. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by somatostatin analogue. Biochem. Biophys. Res. Commun. 203: 253-259, 1994.
31. Rugger, B.A. Klurfeld, D.M. Kritcbevsky, D. and Furlanetto, R.W. Growth factor binding to 7, 12-dimethylbenz(a)anthracene-induced mammary tumors from rat subject to chronic calorie restriction. Cancer Res. 49: 4135-4141, 1989.
32. Peyrat, J.P. Bonnetene, J. Vennin, P.H. Jammes, H. Beuscart, R. Hecquet, B. Djiane, J. Lefebvre, J. and Demaille, A. Insulin-like growth factor I receptors (IGFI-R) and IGF-I in human breast tumors. J. Steroid Biochem. Mol. Biol. 37: 823-827, 1990.
33. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet, 339: 1-15, 1992.